ARTICLES

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.

F. Longo-Munoz, G. Argiles, J. Tabernero, A. Cervantes, C. Gravalos, C. Pericay, S. Gil-Calle, H. Mizuguchi, A. Carrato-Mena,M.L. Limon, R. Garcia-Carbonero.

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A.

Pleomorphic cutaneous Rosai-Dorfman disease.

Martínez-Ciarpaglini C, Saus C, Rojas-Ferrer N, Terrádez L, Serra M, Botella-Estrada R, Monteagudo C.

Genetic 3’UTR variation is associated with human pigmentation characteristics and sensitivity to sunlight.

Hernando B, Peña-Chilet M, Ibarrola-Villava M, Martin-Gonzalez M, Gomez-Fernandez C, Ribas G, Martinez-Cadenas C.

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials.

Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F.

Self-expanding metallic stent as a bridge to surgery in the treatment of left colon cancer obstruction: Cost-benefit analysis and oncologic results.

Flor-Lorente B, Báguena G, Frasson M, García-Granero A, Cervantes A, Sanchiz V, Peña A, Espí A, Esclapez P, García-Granero E.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

The changes in resting anal pressure after performing full-thickness rectal advancement flaps.

Balciscueta Z, Uribe N, Mínguez M, García-Granero E.

The relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileo-caecal resection: an international snapshot audit.

2015 European Society of Coloproctology collaborating group.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AM, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJ, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group.

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.

Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R, Spanish Lung Cancer Group.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O’Brien ME, Yap TA.

Laparoscopy may decrease morbidity and length of stay after elective colon cancer resection, especially in frail patients: results from an observational real-life study.

Cerdán Santacruz C, Frasson M, Flor-Lorente B, Ramos Rodríguez JL, Trallero Anoro M, Millán Scheiding M, Maseda Díaz O, Dujovne Lindenbaum P, Monzón Abad A, García-Granero Ximenez E, ANACO Study Group.

Controversies in the multimodality management of locally advanced rectal cancer.

Díaz Beveridge R, Akhoundova D, Bruixola G, Aparicio J.

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A.

Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.

Martorell PM, Huerta M, Quilis AC, Abellán R, Seda E, Blesa S, Chaves FJ, Beltrán DD, Keränen SR, Franco J, Insa A.

Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sørensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema M, Langenberg MH, de Jonge MJA, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Harring SV, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen U.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Individual surgeon is an independent risk factor for leak after double-stapled colorectal anastomosis: An institutional analysis of 800 patients.

García-Granero E, Navarro F, Cerdán Santacruz C, Frasson M, García-Granero A, Marinello F, Flor-Lorente B, Espí A.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, et al.

Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.

Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado HA, Poveda A, Eisenhauer E, Tu D, Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and Treatment of Cancer—Gynecologic Cancer Group (EORTC-GCG) and the Grupo de Investigación de Cáncer de Ovario (GEICO)

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.

Martínez MT, Pérez-Fidalgo JA, Martín-Martorell P, Cejalvo JM, Pons V, Bermejo B, Martín M, Albanell J, Lluch A

Anastomotic leakage after colon cancer resection: does the individual surgeon matter?

Marinello FG, Baguena G, Lucas E, Frasson M, Hervás D, Flor-Lorente B, Esclapez P, Espí A, García-Granero E.

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.

Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J.

Risk factors for anastomotic leak and postoperative morbidity and mortality after elective right colectomy for cancer: results from a prospective, multicentric study of 1102 patients.

Frasson M, Granero-Castro P, Ramos Rodríguez JL, Flor-Lorente B, Braithwaite M, Martí Martínez E, Álvarez Pérez JA, Codina Cazador A, Espí A, Garcia-Granero E, ANACO Study Group.

Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.

Reynés G, Martínez-Sales V, Vila V, Balañá C, Pérez-Segura P, Vaz MA, Benavides M, Gallego O, Palomero I, Gil-Gil M, Fleitas T, Reche E.

El tratamiento no quirúrgico del cáncer de recto localizado es una opción experimental

Roselló S, Cervantes A.

Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.

Gambardella V, Tarazona N, Cejalvo JM, Roselló S, Cervantes A.

Personalised Treatment in Gastric Cancer: Myth or Reality?

Tarazona N, Gambardella V, Huerta M, Roselló S, Cervantes A

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, Glimelius B, Cervantes A, Thomas J, Begum R, Oates J, Chau I

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.

Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A.

Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin.

Hernando B, Ibarrola-Villava M, Fernandez LP, Peña-Chilet M, Llorca-Cardeñosa M, Oltra SS, Alonso S, Boyano MD, Martinez-Cadenas C, Ribas G.

Assessing PTEN Subcellular Localization

Gil A, López JI, Pulido R.

8P EGFR, KRAS, BRAF, and PI3K mutations and ALK rearrangement in 327 consecutive Spanish non-squamous NSCLC patients.

Martorell PM, Huerta M, Quilis AC, Abellán M, Blesa S, Chaves F, Beltrán DD, Nascimento AF, Insa A.

Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?

Smyth EC, Tarazona N, Peckitt C, Armstrong E, Mansukhani S, Cunningham D, Chau I.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, Cutts R, Campbell J, Ning J, Fenwick K, Swain A, Brown G, Chua S, Thomas A, Johnston SR, Ajaz M, Sumpter K, Gillbanks A, Watkins D, Chau I, Popat S, Cunningham D, Turner NC.

Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma.

Tarazona N, Smyth EC, Peckit C, Chau I, Watkins D, Rao S, Starling N, Cunningham D.

Pigmented desmoplastic trichilemmoma.

Martínez-Ciarpaglini C, Monteagudo C.

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer – A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.

Breugom AJ, Bastiaannet E, Boelens PG, Iversen LH, Martling A, Johansson R, Evans T, Lawton S, O’Brien KM, Van Eycken E, Janciauskiene R, Liefers GJ, Cervantes A, Lemmens VE, van de Velde CJ.

Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project.

Tagliabue E, Gandini S, García-Borrón JC, Maisonneuve P, Newton-Bishop J, Polsky D, Lazovich D, Kumar R, Ghiorzo P, Ferrucci L, Gruis NA, Puig S, Kanetsky PA, Motokawa T, Ribas G, Landi MT, Fargnoli MC, Wong TH, Stratigos A, Helsing P, Guida G, Autier P, Han J, Little J, Sera F, Raimondi S, M-SKIP Study group.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N.

Treatment sequence of synchronously (liver) metastasized colon cancer.

Gruenberger T, Beets G, Van Laethem JL, Rougier P, Cervantes A, Douillard JY, Figueras J, Gruenberger B, Haller DG, Labianca R, Maleux G, Roth A, Ducreux M, Schmiegel W, Seufferlein T, Van Cutsem E.

Three-dimensional endoanal ultrasound for diagnosis of perianal fistulas: Reliable and objective technique.

Garcés-Albir M, García-Botello SA, Espi A, Pla-Martí V, Martin-Arevalo J, Moro-Valdezate D, Ortega J.

MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.

Fleitas T, Ibarrola-Villava M, Ribas G, Cervantes A.

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.

Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A.

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T.

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.

Cejalvo JM, Pérez-Fidalgo JA, Ribas G, Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B, Martínez MT, Cervantes A, Lluch A.

Sex and MC1R variants in human pigmentation: Differences in tanning ability and sensitivity to sunlight between sexes.

Hernando B, Ibarrola-Villava M, Peña-Chilet M, Alonso S, Ribas G, Martinez-Cadenas C.

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, ESMO Guidelines Committee.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, ESMO/ASCO Global Curriculum Working Group.

In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.

Riffo-Campos ÁL, Castillo J, Vallet-Sánchez A, Ayala G, Cervantes A, López-Rodas G, Franco L.

25-Hydroxyvitamin D in Patients With Melanoma and Factors Associated With Inadequate Levels.

Hernández-Ostiz S, Pérez-Ramada MD, Ortiz B, Requena C, Ribas G, Aznar E, Nagore E.